Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major [PDF]
Journal of Cardiovascular Magnetic Resonance, 2012 Background Combination therapy with deferoxamine and oral deferiprone is superior to deferoxamine alone in removing cardiac iron and improving left ventricular ejection fraction (LVEF).
Alpendurada Francisco +9 more
doaj +2 more sources
Application of Deferoxamine in Tissue Regeneration Attributed to Promoted Angiogenesis [PDF]
MoleculesDeferoxamine, an iron chelator used to treat diseases caused by excess iron, has had a Food and Drug Administration-approved status for many years. A large number of studies have confirmed that deferoxamine can reduce inflammatory response and promote ...
Haijun Shen +5 more
doaj +2 more sources
Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats [PDF]
Neural Regeneration Research, 2017 Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the mechanism for this action remains unknown.
Jian Hao +10 more
doaj +2 more sources
Improving adherence with deferoxamine regimen in thalassemia major using education [PDF]
Iranian South Medical Journal, 2006 Background: Subcutaneous deferoxamine is the first line for management of iron overload in thalassemia major. There is a wide deferoxamine adherence variation in patients with thalassemia major.
Gholamreza Pouladfar, Mandana Moaiedfard
doaj +1 more source
Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior [PDF]
Caspian Journal of Internal Medicine, 2017 Background: Cardiac complications due to iron overload are the most common cause of death in patients with thalassemia major. The aim of this study was to compare iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and ...
Shahla Ansari +4 more
doaj +1 more source
Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson’s Disease Mice [PDF]
International Journal of NanomedicineYiming Huang,1,* Xinran Wang,1,* Wenjing Li,1,* Feng Yue,1,2 Miao Wang,1 Feifan Zhou1,2 1State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya, People’s Republic of China; 2One Health ...
Huang Y +5 more
doaj +2 more sources
Deferoxamine deconditioning increases neuronal vulnerability to hemoglobin [PDF]
, 2020 Hypothesis: Deferoxamine pretreatment and abrupt withdrawal increases the vulnerability of neurons to hemoglobin. Model: Primary cortical cell cultures (murine); cultures were pretreated with deferoxamine alone, deferoxamine plus hemoglobin, or vehicle ...
Regan, R (via Mendeley Data)
core +5 more sources
Deferoxamine and Curcumin Loaded Nanocarriers Protect Against Rotenone-Induced Neurotoxicity [PDF]
, 2020 Background: Reduced glutathione and excess free iron within dopaminergic, substantia nigra neurons in Parkinson's disease (PD) can drive accumulation of toxic hydroxyl radicals resulting in sustained oxidative stress and cellular damage.
Zariwala, M. +2 more
core +1 more source
Reduced sulfatide content in deferoxamine-induced senescent HepG2 cells [PDF]
, 2023 Iron chelators, such as deferoxamine, exert an anticancer effect by altering the activity of biomolecules critical for regulation of the cell cycle, cell metabolism, and apoptotic processes.
Bresci, Arianna +15 more
core +1 more source
Value of black blood T2*cardiovascular magnetic resonance. [PDF]
, 2011 Purpose To assess whether black blood T2* cardiovascular magnetic resonance is superior to conventional white blood imaging of cardiac iron in patients with thalassaemia major (TM).
Gillian C Smith +17 more
core +1 more source